Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential.

Abstract

The recent outbreak of coronavirus disease 2019 (COVID-19) highlights an urgent need for therapeutics. Through a series of drug repurposing screening campaigns, niclosamide, an FDA-approved anthelminthic drug, was found to be effective against various viral infections with nanomolar to micromolar potency such as SARS-CoV, MERS-CoV, ZIKV, HCV, and human adenovirus, indicating its potential as an antiviral agent. In this brief review, we summarize the broad antiviral activity of niclosamide and highlight its potential clinical use in the treatment of COVID-19.

• Authors: Jimin Xu, Pei-Yong Shi, Hongmin Li, Jia Zhou
• Journal: ACS infectious diseases (ACS Infect Dis) Vol. 6 Issue 5 Pg. 909-915 (05 08 2020) ISSN: 2373-8227 [Electronic] United States
• PMID: 32125140 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Review)

Chemical References

• Antiviral Agents
• Niclosamide

Topics

• Antiviral Agents (pharmacology)
• Betacoronavirus (drug effects)
• COVID-19
• Coronavirus Infections (drug therapy)
• Drug Repositioning
• Humans
• Middle East Respiratory Syndrome Coronavirus (drug effects)
• Niclosamide (pharmacology)
• Pandemics
• Pneumonia, Viral (drug therapy)
• Severe acute respiratory syndrome-related coronavirus (drug effects)
• SARS-CoV-2
• COVID-19 Drug Treatment